Association Between PD-L1/CD8 Expression and Outcomes in Melanoma Patients Who Received Dabrafenib/Trametinib
Jeffrey Weber, MD, PhD: The Association Between Durable Response and Low Disease BurdenAugust 17th 2016
Jeffrey Weber, MD, PhD: Predicting Which Patients Will Experience Durable Responses to Targeted TherapyAugust 17th 2016
Jeffrey Weber, MD, PhD: The Role of LDH, Age, and Sites of Disease in Durability of ResponseAugust 17th 2016
Jason Luke, MD: Predicting Which Patients Will Experience Durable Responses to Targeted TherapyAugust 17th 2016
Metastatic Melanoma with Jason Luke, MD and Jeffrey Weber, MD, PhD: Case 1August 16th 2016Metastatic Melanoma with Jason Luke, MD and Jeffrey Weber, MD, PhD
Jason Luke, MD: The Impact of Moderate Level of Disease Burden on Response to Targeted TherapyAugust 16th 2016
Jeffrey Weber, MD, PhD: The Impact of Moderate Level of Disease Burden on Response to Targeted TherapyAugust 16th 2016
Metastatic Melanoma with Adil Daud, MD and Boris C. Bastian, MD, PhDAugust 3rd 2016Metastatic Melanoma with Adil Daud, MD and Boris C. Bastian, MD, PhD